XERS Stock Recent News

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q1 2025 Results Conference Call May 8, 2025 8:30 AM ET Company Participants Allison Wey - SVP of IR, Corporate Communications John Shannon - CEO Steve Pieper - CFO Conference Call Participants David Amsellem - Piper Sandler Eason Lee - Leerink Partners Jason Dorr - Oppenheimer Chase Knickerbocker - Craig-Hallum Operator Good morning. Thank you for attending today's Xeris Biopharma First Quarter 2025 Results Conference Call.

Xeris Biopharma (XERS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.14 per share a year ago.

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the first quarter ended March 31, 2025, and updated its fiscal 2025 total revenue guidance. “We're very pleased with our strong start to the year, delivering another quarter of outstanding revenue growth,” said John Shannon, Xe.

Xeris Biopharma Holdings, Inc. has shown consistent double-digit growth and is expected to continue this trend, with Q1 earnings projected to drive the share price higher. Key metrics to watch include Gvoke and Recorlev revenues, EPS, adjusted EBITDA, and cash flow, as these will determine Xeris's path to profitability. Risks include potential underperformance in product revenue, rising SG&A expenses, and any delays in pipeline programs like XP-8121.

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced changes to its board of directors. Ricki Fairley has resigned from the board in light of other commitments, effective immediately. The Board of Directors has appointed James Brady as a new director of Xeris' board to fill the vacancy. In addition.

Xeris Biopharma (XERS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q4 2024 Earnings Conference Call March 6, 2025 8:30 AM ET Company Participants Allison Wey - SVP of IR, Corporate Communications John Shannon - CEO Steve Pieper - CFO Conference Call Participants Chase Knickerbocker - Craig-Hallum Oren Livnat - H.C. Wainwright Glen Santangelo - Jefferies David Amsellem - Piper Sandler Leland Gershell - Oppenheimer Mazahir Alimohamed - Leerink Partners Operator Good morning, and welcome to the Xeris Biopharma Fourth Quarter and Full Year 2024 Financial Results.

Although the revenue and EPS for Xeris Biopharma (XERS) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Xeris Biopharma (XERS) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.10 per share a year ago.

Xeris Biopharma (XERS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.